Company intelligence / Profile preview
Shijiazhuang Zhikang Hongren New Drug Development
Shijiazhuang, Hebei, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Shijiazhuang Zhikang Hongren New Drug Development focuses on small molecule drug development for oncology and other therapeutic areas. The company has several candidates in early clinical stages targeting kinases such as WEE1 and ATR for cancer indications. Its lead asset SC‑0062 is an ETA antagonist that has reached Phase 3 clinical trials for proteinuria-related indications. Other assets are in earlier phases targeting solid tumors with FGFR or ATR inhibitors
- Therapeutic areas
- OncologyPulmonologyEndocrinologyGastroenterology
- Modalities
- Small moleculeAntibody (for some programs via related entities)Antibody-drug conjugate (for some programs via related entities)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
No major global pharmaceutical partnerships publicly disclosed.
Beyond the preview
Go deeper on Shijiazhuang Zhikang Hongren New Drug Development.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shijiazhuang Zhikang Hongren New Drug Development.